Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced positive topline results from the Phase 3 ZENITH study evaluating WINREV...
GSK plc (LSE/NYSE: GSK) announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved a regulatory application to extend the indi...
Launch follows approval by Japanese Ministry of Health, Labour and Welfare in September 2024 — Milestone payment to be made to HUTCHMED fro...
AstraZeneca’s Tagrisso (osimertinib) has been recommended for approval in the European Union (EU) for the treatment of adult patients with ...
Eli Lilly and Company (NYSE: LLY) announced positive results from the TRAILBLAZER-ALZ 6 Phase 3b study, showing a reduction in amyloid-related imaging...
Novartis presented 12-month data from the Phase III APPEAR-C3G study at American Society of Nephrology (ASN) Kidney Week 2024 showing that patients with C3...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi will present positive data from the Phase 3 LIBERTY-CUPID Study C evaluating the inves...
INCHEON, South Korea, Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), announced a contra...
Eli Lilly and Company (NYSE: LLY) announced data demonstrating more patients with moderately to severely active Crohn's disease treated with miri...
The approval of QUVIVIQ™, a novel dual orexin receptor antagonist, is based on robust clinical efficacy and safety data, including from a Phase 3...
— Approval based on results from global Phase III FRESCO-2 trial in patients with previously treated metastatic colorectal cancer — &md...
New digital health solution for heart failure management puts patients at the center of their care by providing ability for at-home disease monitoring -...
Approval underscores CSL and Arcturus Therapeutics' commitment to delivering disruptive technologies to combat COVID-19 and other respiratory viral disea...
Nxera Pharma Co – formerly known as Sosei Group or Sosei Heptares – announces that it will receive a US$35 million payment from Neurocrine Bi...
© 2025 Biopharma Boardroom. All Rights Reserved.
